top of page


On September 8, 2022-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFYTM (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.1 DAXXIFYTM is the first and only neuromodulator stabilized with Peptide Exchange TechnologyTM (PXT) and is free of both human serum albumin and animal-based components.1-2,7-11 Most importantly, DAXXIFYTM has the ability to address duration of treatment effect, which we believe is the greatest unmet need with existing neuromodulators for both consumers and injectors laying the groundwork for potential future therapeutic indications.

  • 74% of subjects achieved a > two-grade improvement in glabellar lines at week 4 per both investigator and patient assessment

  • 6-month median duration

  • Some patients maintained treatment results at 9 months

  • Results seen as early as one day after treatment, typically seen within two days

Cost will likely be about $18 per unit

40 views0 comments

Recent Posts

See All
bottom of page